CY1111517T1 - Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης - Google Patents

Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης

Info

Publication number
CY1111517T1
CY1111517T1 CY20111100414T CY111100414T CY1111517T1 CY 1111517 T1 CY1111517 T1 CY 1111517T1 CY 20111100414 T CY20111100414 T CY 20111100414T CY 111100414 T CY111100414 T CY 111100414T CY 1111517 T1 CY1111517 T1 CY 1111517T1
Authority
CY
Cyprus
Prior art keywords
dihydroimidazolo
hydroxylation
dopamine
thionyl
inhibitors
Prior art date
Application number
CY20111100414T
Other languages
Greek (el)
English (en)
Inventor
DA SILVA Patrício Manuel Viera Araújo SOARES
David Alexander Learmonth
Alexander Beliaev
Original Assignee
Bial - Portela & Ca., S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial - Portela & Ca., S.A. filed Critical Bial - Portela & Ca., S.A.
Publication of CY1111517T1 publication Critical patent/CY1111517T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20111100414T 2007-05-08 2011-04-26 Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης CY1111517T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
EP08741778A EP2155731B1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
CY1111517T1 true CY1111517T1 (el) 2015-08-05

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100414T CY1111517T1 (el) 2007-05-08 2011-04-26 Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης

Country Status (29)

Country Link
US (5) US8481582B2 (enExample)
EP (1) EP2155731B1 (enExample)
JP (1) JP5559677B2 (enExample)
KR (1) KR101598482B1 (enExample)
CN (1) CN101687858B (enExample)
AR (2) AR066457A1 (enExample)
AT (1) ATE499367T1 (enExample)
AU (1) AU2008246443B2 (enExample)
BR (1) BRPI0811275B8 (enExample)
CA (1) CA2686387C (enExample)
CL (1) CL2008001321A1 (enExample)
CY (1) CY1111517T1 (enExample)
DE (1) DE602008005141D1 (enExample)
DK (1) DK2155731T3 (enExample)
ES (1) ES2360841T3 (enExample)
GB (1) GB0708818D0 (enExample)
HR (1) HRP20110253T1 (enExample)
IL (1) IL201921A (enExample)
MX (1) MX2009012041A (enExample)
NO (1) NO20093275L (enExample)
NZ (1) NZ580962A (enExample)
PL (1) PL2155731T3 (enExample)
RS (1) RS51692B (enExample)
RU (1) RU2501796C2 (enExample)
SI (1) SI2155731T1 (enExample)
TW (1) TWI458722B (enExample)
UA (1) UA104844C2 (enExample)
WO (1) WO2008136695A1 (enExample)
ZA (1) ZA200908612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
WO2012020742A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
PT2655363T (pt) * 2010-12-22 2017-07-13 Bial-Portela & Ca S A Formas cristalinas e processos para a sua preparação
JP5981539B2 (ja) * 2011-06-29 2016-08-31 バイアル−ポルテラ アンド シーエー，エス．エー． プロセス
DK2919780T3 (en) * 2012-11-14 2018-11-26 Bial Portela & Ca Sa 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
WO2019112457A1 (en) * 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
AU2019381628A1 (en) * 2018-11-12 2021-05-27 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
AU2022213938A1 (en) * 2021-01-26 2023-09-07 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
ES2201104T3 (es) 1994-04-26 2004-03-16 Roche Palo Alto Llc Derivados de benzociclohexilimidazoltiona.
AR032711A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
IL201921A (en) 2013-11-28
KR101598482B1 (ko) 2016-02-29
US20170369478A1 (en) 2017-12-28
UA104844C2 (uk) 2014-03-25
US20130345275A1 (en) 2013-12-26
US20210261533A1 (en) 2021-08-26
US9630951B2 (en) 2017-04-25
IL201921A0 (en) 2010-06-16
PL2155731T3 (pl) 2011-07-29
JP5559677B2 (ja) 2014-07-23
AU2008246443A1 (en) 2008-11-13
US8481582B2 (en) 2013-07-09
AU2008246443A8 (en) 2010-01-07
GB0708818D0 (en) 2007-06-13
ZA200908612B (en) 2010-11-24
DE602008005141D1 (de) 2011-04-07
BRPI0811275B8 (pt) 2021-05-25
DK2155731T3 (da) 2011-05-02
WO2008136695A1 (en) 2008-11-13
ES2360841T3 (es) 2011-06-09
EP2155731A1 (en) 2010-02-24
HRP20110253T1 (hr) 2011-05-31
CN101687858A (zh) 2010-03-31
RS51692B (sr) 2011-10-31
CA2686387A1 (en) 2008-11-13
BRPI0811275A2 (pt) 2014-12-23
US20190322648A1 (en) 2019-10-24
RU2009145270A (ru) 2011-06-20
AR112789A2 (es) 2019-12-11
BRPI0811275B1 (pt) 2020-01-07
CA2686387C (en) 2015-06-30
TW200918525A (en) 2009-05-01
NO20093275L (no) 2010-02-04
JP2010526136A (ja) 2010-07-29
US20100137390A1 (en) 2010-06-03
CL2008001321A1 (es) 2008-12-26
HK1142898A1 (en) 2010-12-17
RU2501796C2 (ru) 2013-12-20
TWI458722B (zh) 2014-11-01
AR066457A1 (es) 2009-08-19
EP2155731B1 (en) 2011-02-23
KR20100017546A (ko) 2010-02-16
ATE499367T1 (de) 2011-03-15
AU2008246443B2 (en) 2013-07-11
MX2009012041A (es) 2010-02-18
NZ580962A (en) 2012-05-25
SI2155731T1 (sl) 2011-05-31
CN101687858B (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
MX2009012041A (es) Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
MY141229A (en) Piperidine-benzenesulfonamide derivatives
NO20053748L (no) Pyrrolopyridazinderivater.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NO20062370L (no) Amidderivater
CY1117080T1 (el) Θεραπευτικος παραγοντας για στενωση του σπονδυλικου σωληνα
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
TW200833675A (en) Nicotinamide derivatives
DE602005016261D1 (de) Substituierte arylaminderivate und verwendungsverfahren
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20083917L (no) Malonamidderivater som gammasekretaseinhibitorer
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
MY193754A (en) Treatment for parkinson's disease
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
CY1120953T1 (el) Παραγωγα 1,3-διυδροϊμιδαζολο-2-θειονης για χρηση στην αγωγη πνευμονικης αρτηριακης υπερτασης και πνευμονικης βλαβης
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
BRPI0518117A (pt) uso de um derivado de piridotienopirimidina, composição farmacêutica, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de cura pela inibição da fosfodiesterase 4 e produto de combinação
EA201001470A1 (ru) Производные 5-гидрокси-4-аминометил-l-циклогексил (или циклогептил)-3-алкоксикарбонилиндолов, их фармацевтически приемлемые соли, обладающие противовирусной активностью, и способ их получения
EA200970046A1 (ru) Аминопроизводные в-гомоандростанов и в-гетероандростанов